Preclinical vs Phase 2 — Immunology Deal Valuation Comparison

Preclinical Median Upfront

$63M

Total: $904M

Phase 2 Median Upfront

$480M

Total: $2.5B

Stage Premium

177%

Phase 2 premium over Preclinical

Preclinical Royalties

5.5%-11%

vs Phase 2: 13.2%-22.1%

Model Your Deal

Market Analysis

The Preclinical to Phase 2 transition in immunology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $2.5B compared to $904M at Preclinical, a 177% premium reflecting clinical de-risking. Upfront payments increase from $63M to $480M.

Deal structures shift as assets advance. Preclinical deals allocate 7% to upfront and 93% to milestones, while Phase 2 deals shift to 19%/81%. Development milestones move from $378M to $405M, and royalty rates evolve from 5.5%-11% to 13.2%-22.1%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Preclinical to Phase 2 in immunology?

Phase 2 immunology deals command a 177% premium over Preclinical in total deal value ($2.5B vs $904M). Upfronts increase from $63M to $480M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Preclinical and Phase 2 in immunology?

Preclinical deals are more milestone-weighted (93% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (19% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a immunology asset?

The optimal licensing window depends on strategic priorities. Preclinical assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 177% premium from Preclinical to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included